Investor Relations or Corporate Communications

SONDRA S. NEWMAN PROFESSIONAL OVERVIEW Corporate communications and investor relations professional with over 11 years of experience establishing and implementing effective public relations and commu nications strategies for both publicly-traded and privately-funded companies, pr imarily in the life sciences. Excellent client service history as both an intern al and agency provider. Proven aptitude for distilling complex science into audi ence-specific soundbytes. Demonstrated ability to establish, nurture and leverag e relationships across internal disciplines and with external constituents and s takeholders. Strong writing, presentation, organizational and analytical skills. EXPERIENCE NEWCOMM ADVISORS, Boston, MA Owner 12/2006 - PRESENT

Strategic corporate communications and investor relations (IR) consultancy, main ly serving biopharmaceutical and technology-driven companies. * For AMAG Pharmaceuticals, developed an integrated communications plan and esta blished the IR function for the company in preparation for an internal hire and leading up to the commercial launch of iron-deficiency product ferumoxytol. * For IDT Biologika GmbH, developed U.S. media strategy and conducted outreach t o raise visibility for this contract manufacturer of vaccines and biologics. Obt ained broad coverage, including a video interview, and secured editorial article s in key publications including, Drug Discovery & Development, FierceVaccines an d FiercePharma Manufacturing, Contract Pharma and Outsourcing-Pharma. * For AIKO Biotechnology, prepared and implemented media strategy to announce ap pointment of company's first CEO and raise awareness of the company's clinical d evelopment programs in opioid abuse deterrence and side effect mitigation. Condu cted outreach and secured coverage of news in regional press and key industry tr ades including BioCentury, BioWorld, BioSpace, Drug Discovery & Development, Gen etic Engineering News, Mass High Tech and PharmaLive. * For Substructure Inc., established and executed the media relations function f or this underwater services and marine design company. Prepared articles and whi te papers appearing in Roads & Bridges, Inland Port and regional newspapers to h ighlight the company's state-of-the-art hydrographic surveying and mapping capab ilities. * For Kittery Land Trust, elevated media outreach efforts to increase awareness and drive membership. PURE COMMUNICATIONS, INC., Boston, MA 8/2007 - 1/2011 Senior Communications Counselor (Contractor) Responsible for development and implementation of integrated communications and IR programs for biotechnology clients of this 30-person virtual agency. Duties i ncluded corporate communications strategy development, budget planning, key mess age platform development, writing (press releases, Q&A documents, management scr ipts, marketing materials), media targeting and outreach and crisis planning. Al so included were investor and analyst relations, financing and IPO planning, me rger and acquisition support, as well as patient advocacy and thought leader dev

elopment. * For Bioenvision, Inc., counseled board and executive management team during sh areholder-contested acquisition by Genzyme Corporation; proxy solicitation led t o successful completion of transaction at 50% premium to 20-day average sharepri ce. * For Infinity Pharmaceuticals, participated in the development of a crisis plan to communicate the halt of a phase III clinical trial for the company's lead c ompound; event was successfully positioned to minimize negative impact and posit ively reflect on management credibility. * For Sirtris Pharmaceuticals, prepared nominations resulting in Scrip Award for Biotech Company of the Year, the Stevie(R) Award for Executive of the Year 2009 (CEO Christoph Westphal) and Mass High Tech Deal of the Year recognition, follo wing on industry-lauded acquisition of Sirtris by Glaxo SmithKline. * For Concert Pharmaceuticals, secured coveted "Emerging Company" profile in Bio Century to increase visibility for this startup company's novel approach to crea ting patently differentiated versions of existing small molecule drugs. Also sec ured company as a Fierce Biotech "Fierce 15" winner, so named for corporate visi on, strength of technology, and competitive market position. * Also for Concert Pharmaceuticals, conducted initial strategic mapping sessions , facilitated production and launch of website, established corporate communicat ions function to prepare company for internal hire. * For Predictive Biosciences, developed and executed on a communications integra tion plan following the company's acquisition of a complementary lab services bu siness. Also ensured consistent media coverage and investor/analyst exposure for this molecular diagnostics company. * For AVEO Pharmaceuticals, created corporate presentation and communications st rategy to announce flagship deal with Biogen Idec to advance development-stage o ncology product candidates. * For Lantheus Medical Imaging, prepared crisis communications documents during onset of global radioisotope shortage impacting availability of Lantheus' princi pal commercial products for cardiac imaging; managed media inquiries; successful ly positioned Lantheus as resourceful and trustworthy. * Also for Lantheus Medical Imaging, worked with management to establish quarter ly SEC filings and earnings conference calls following issuance of restricted no tes and subsequent exchange offer. * For InfraReDx, Inc., arranged interview with the New York Times and conducted ongoing media outreach resulting in features in several key publications to high light first-in-class LipiScan IVUS intracoronary imaging device. Feature coverag e includes Cath Lab Digest, Diagnostic & Interventional Cardiology, Dow Jones Ve ntureWire, The Gray Sheet, IN VIVO. * Also for InfraReDx, Inc., participated as core team member to conduct strategi c roadmapping session, refresh corporate messaging and develop new marketing col lateral including booth design and copy, corporate and product fact sheets, B-ro ll video. * For GeminX Pharmaceuticals and Predictive Biosciences, supported multiple vent ure capital raises and business development efforts with investor and media intr oductions. Media results include features in BioWorld, Fierce Biotech, Drug Disc overy & Development, Dow Jones VentureWire.

NITROMED, INC., Lexington, MA Director, Investor Relations

9/2005 - 11/2006

Reporting to Vice President, Corporate Communications, responsible for developme nt and implementation of IR programs and strategies that facilitated research an alysts' coverage of the company and its congestive heart failure drug BiDil(R), the first-ever drug targeted specifically to African Americans. Appointed to int ernal taskforce that led brand and collateral strategy development. Managed outs ide vendors and significant budget. By request, consulted for NitroMed following a major downsizing and ultimate sale of the company and it assets. * Provided media support to obtain placements in national news outlets including The Wall Street Journal, The Economist and National Public Radio as well as key trade publications like BioWorld and BioCentury. * Proactively managed external communications through multiple shifts in leaders hip and sales strategies. Also coordinated internal "town meetings" for manageme nt to position and discuss these shifts. * Fostered relationships with bankers and research analysts at Cowen & Company, Deutsche Bank, Friedman Billings Ramsey, JP Morgan, Merrill Lynch, Pacific Growt h Equities and UBS. * Influenced substantial reduction in company's short position, from 30% to 8% i nterest over a 12-month period. * Developed and distributed employee newsletter to inform national sales staff o f corporate strategy and developments. DYAX CORPORATION, Cambridge, MA 3/2002 - 8/2005 Director, Corporate Communications & Investor Relations Responsible for development and implementation of communications and IR programs that drove awareness of the company and its pipeline of compounds for the treat ment of cancer and auto-immune disorders. Managed outside public relations and I R agencies, and significant outside services budget. * Conducted news-driven and opportunistic editorial calendar media outreach to s ecure consistent coverage in consumer and trade publications. In addition to tra de publication coverage, highlights included CNBC video interview of CEO, inclus ion in the Wall Street Journal series on orphan drug development and coverage by New England Cable News. * Coordinated highly attended "Orphan Drug Advances" media and analyst event in New York; podium speakers included Dyax CEO, Genzyme CEO, patients and advocacy group leaders, medical thought leaders and regulatory experts. * Conceptualized design and developed copy for award-winning annual report; mana ged agency process and met on-time filings and delivery of report. * Led website redesign and launch project to support commercial direction of the company; managed creation of B-roll in conjunction with website and other commu nications initiatives. ALTAREX CORP., Waltham MA 1/2000 - 1/2002 Director, Investor Relations & Corporate Communications

Responsible for corporate communications, media relations, crisis communications and investor relations for this TSE-traded biotechnology company focused on dev elopment and commercialization of murine antibodies as immunotherapeutics for th e treatment of cancer. Lead product ultimately out-licensed to United Therapeut ics. * Obtained coverage in trade and consumer publications including feature stories on ovarian cancer in Ladies Home Journal and Family Circle; developed and imple mented IR strategy that resulted in increased sellside analyst coverage; establi shed and sustained successful advocacy group partnerships. WARREN & MORRIS, LTD., Portsmouth, NH Executive Search Consultant 3/1998 - 12/1999

MEDIAONE, Andover, MA (now Comcast) 1991 - 1997 Director, Marketing Analysis & Competitive Intelligence, 1995 - 1997 Manager, Marketing Analysis, 1991 - 1995 PERSONAL - Sondra Newman Location: Bedford, MA Kittery Point, ME Telephone/Email: 617-877-5687 207-439-0988 [email protected] ~OR~ [email protected] Education: Wharton School of Business, University of Pennsylvania, Philadelphia, PA B. Sc Economics, 1987